Tiny study hints at imaging tool to predict meningioma treatment success
NCT ID NCT06614205
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at 11 patients with meningioma (a type of brain tumor) who received a treatment called 177Lu-DOTATATE. Researchers used special scans to measure how much radiation the tumors absorbed, and checked if that could predict whether patients would survive without the tumor growing for at least 6 months. The goal is to see if this imaging method can help guide treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-DOTATATE
What this could lead to
If successful, this could help doctors predict which patients will benefit most from 177Lu-DOTATATE treatment for meningioma.
What could go wrong
This is a very small, completed study with only 11 patients. Results may not apply to all patients, and the imaging method may not reliably predict outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGIOMA OF BRAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU de NANCY
Vandœuvre-lès-Nancy, 54511, France
-
Nuclear medicine Department CHRU de NANCY
Vandœuvre-lès-Nancy, 54511, France